Mesoblast FY26 net loss narrows 44% to US$57.5 million; revenue more than doubled to US$120.3 million

Reuters2026/08/27 00:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Mesoblast posted FY2026 revenue of US$120.3 million, up from US$17.2 million a year earlier, on Ryoncil launch momentum.
Net loss narrowed 44% to US$57.5 million; gross profit rose to US$103.6 million as product sales climbed to US$115.2 million.
R&D expense increased to US$97.5 million; selling, general and administration costs rose to US$57.3 million.
Net operating cash spend was US$43.8 million; cash and cash equivalents ended at US$103 million following a US$125 million credit-line facility.
Management flagged Phase 3 treatment completion for rexlemestrocel-L in chronic low back pain, with top-line results expected mid-CY2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608262032PRIMZONEFULLFEED9816905) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Mesoblast FY26 net loss narrows 44% to US$57.5 million; revenue more than doubled to US$120.3 million

You may also like

Crypto prices